Steroids with or without blood thinners for Behçet's vein clots
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Behçet's syndrome according to international criteria.
- You have a first or repeat deep vein blood clot (DVT) confirmed by imaging (ultrasound, CT, or MRI).
- You agree to use effective birth control if you could become pregnant.
- You are not already on blood thinners for another condition, and you have no active bleeding or high bleeding risk.
- You have not been on high-dose steroids for more than 6 weeks or on blood thinners for more than 4 weeks recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This trial compares standard immunosuppressive therapy alone versus adding a blood thinner (rivaroxaban) for treating newly diagnosed blood clots in the legs of people with Behcet's disease. It aims to see if adding the anticoagulant improves clot resolution without increasing bleeding risk.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study looks at how Behçet's disease affects blood clotting. If you have Behçet's disease and are between 18–70, you may help doctors understand why some people with Behçet's develop dangerous blood clots.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
Hear when a new Behcet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.